Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

 Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) Market Outlook

Thelansis’s “Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) Overview

Hematopoietic stem cell transplant (HSCT) is a procedure where healthy hematopoietic stem cells are given to patients with dysfunctional or depleted bone marrow. HSCT therapy is used for both malignant (Acute myeloid leukemia, Myelodysplastic syndromes, Chronic myeloid leukemia, Acute lymphoblastic leukemia, Myeloproliferative disorders, Non-Hodgkin’s lymphoma, Multiple myeloma, Chronic lymphocytic leukemia, Hodgkin’s disease, Juvenile chronic myeloid leukemia)and non-malignant (Aplastic anemia, Paroxysmal nocturnal hemoglobinuria, Fanconi’s anemia, Blackfan-Diamond anemia, Thalassemia major, Sickle cell anemia, Severe combined immunodeficiency, Wiskott-Aldrich syndrome and Inborn errors of metabolism) diseases. In allogeneic hematopoietic stem cell transplantation (HSCT), the stem cells are sourced from a donor different from the recipient. Typically, the donor and recipient share a degree of genetic compatibility known as HLA (human leukocyte antigen) matching, determined by the genes found on chromosome 6. Each individual inherits a set of MHC (major histocompatibility complex) alleles, forming HLA pairs. Crucial HLA loci include HLA-A, HLA-B, HLA-C, HLA-DR, and HLA-DQ. The selection of a donor for allogeneic HSCT considers several factors, including the patient’s specific disease, disease stage, and the urgency of finding a suitable donor. In cases where allogeneic HSCT is being contemplated, having a fully HLA-matched sibling as the donor is the preferred choice. This preference is due to the lower risk of graft rejection and graft-versus-host disease (GvHD) when using allogeneic stem cells from a fully HLA-matched sibling. Stem cells can be obtained from three sources:

  1. Bone Marrow: This involves a surgical procedure using hollow needles to extract liquid bone marrow from the hip bones. Anticoagulants are added to prevent clumping, and sterile filters remove impurities. Bone marrow can be stored at room temperature, in a refrigerator for a limited time, or cryopreserved for longer storage.
  2. Peripheral Blood Progenitor Cells (PBPCs): PBPCs containing HPCs are collected from peripheral blood using an apheresis device. A growth factor is usually administered before collection. Autologous PBPC donors may receive chemotherapy. PBPCs can be stored at room temperature, in refrigerators, or cryopreserved like bone marrow.
  3. Umbilical Cord Blood (UCB): UCB, once considered waste, is collected safely after childbirth. Further processing removes red blood cells, which are cryopreserved for future use. UCB can be stored privately or publicly for unrelated recipients.

Complications following a bone marrow transplant can be acute or chronic and are influenced by various factors, including age, performance status, stem cell source, and preparative regimen. Acute complications occur within the first 90 days, including myelosuppression, sinusoidal obstruction syndrome, mucositis, graft-versus-host disease, bacterial and viral infections, and fungal infections. Chronic complications encompass chronic GVHD, infections with encapsulated bacteria, and varicella-zoster virus reactivation. The number of allogeneic HCTs performed in the USA increased compared to autologous HCTs. The most common type of allogeneic HCT was from an unrelated donor, followed by transplants from a related donor.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

  • In-depth interviews with leading KOLs and payers
  • Physician surveys
  • RWE analysis for claims and EHR datasets
  • Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

  • Detailed Report (PDF)
  • Market Forecast Model (MS Excel-based automated dashboard)
  • Epidemiology (MS Excel; interactive tool)
  • Executive Insights (PowerPoint presentation)
  • Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

  • 10-year market forecast (2024–2034)
  • Bottom-up patient-based market forecasts validated through the top-down sales methodology
  • Covers clinically and commercially-relevant patient populations/ line of therapies
  • Annualized drug-level sales and patient share projections
  • Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
  • Detailed methodology/sources & assumptions
  • Graphical and tabular outputs
  • Users can customize the model based on requirements

Key business questions answered:

  • How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
  • How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
  • What is the 10-year market outlook for sales and patient share?
  • Which events will have the greatest impact on the market’s trajectory?
  • What insights do interviewed experts provide on current and emerging treatments?
  • Which pipeline products show the most promise, and what is their potential for launch and future positioning?
  • What are the key unmet needs and KOL expectations for target profiles?
  • What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
  • and more…


Read more: Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Comments

Post a Comment